{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:04:26Z","timestamp":1790060666714,"version":"4.0.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Desirable product attributes for treatment of moderate-to-severe acute pain in many medically supervised settings are rapid onset and a route of administration not requiring intravenous access. The pharmacokinetic characteristics of sublingually administered tablets containing 15 or 30 \u00b5g of sufentanil are described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood was sampled from healthy subjects (four studies, 122 subjects) and patients (seven studies, 944 patients). Studies in healthy subjects determined bioavailability, effect of inhibition of cytochrome P450 3A4, and the plasma concentration profile with single and hourly sublingual doses. Studies in patients evaluated effects of weight, age, sex, and organ impairment on apparent clearance. Noncompartmental and mixed-effect population methods were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing. Ketoconazole (CYP3A4 inhibitor) increased maximum plasma concentration 19% and increased the area under the curve 77%. After a single 30-\u00b5g dose, plasma concentrations reached the published sufentanil analgesic threshold (24 pg\/ml) within 30\u2009min, peaked at 1\u2009h, and then decreased below therapeutic concentrations by ~3\u2009h. With hourly administration, plasma concentrations plateaued by the fifth dose. Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5\u2009\u00b1\u20090.85\u2009h) and 12 doses (2.5\u2009\u00b1\u20090.72\u2009h). Clearance increased with weight, decreased with age, and was not affected by renal or hepatic impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The time course of a single 30-\u00b5g dose was consistent with onset of analgesia and redosing frequency observed in clinical trials. Sublingual sufentanil tablets provide the opportunity to noninvasively and rapidly treat moderate-to-severe pain in a monitored setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aln.0000000000002145","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T11:00:19Z","timestamp":1519988419000},"page":"943-952","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain"],"prefix":"10.1097","volume":"128","author":[{"given":"Dennis M.","family":"Fisher","sequence":"first","affiliation":[{"name":"From P Less Than, San Francisco, California (D.M.F.); Certara Strategic Consulting, Princeton, New Jersey (P.C., D.R.W.); Leiden University Medical Center, Leiden, The Netherlands (A.D.); and AcelRx Pharmaceuticals, Redwood City, California (P.P.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[{"name":"From P Less Than, San Francisco, California (D.M.F.); Certara Strategic Consulting, Princeton, New Jersey (P.C., D.R.W.); Leiden University Medical Center, Leiden, The Netherlands (A.D.); and AcelRx Pharmaceuticals, Redwood City, California (P.P.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Russell","family":"Wada","sequence":"additional","affiliation":[{"name":"From P Less Than, San Francisco, California (D.M.F.); Certara Strategic Consulting, Princeton, New Jersey (P.C., D.R.W.); Leiden University Medical Center, Leiden, The Netherlands (A.D.); and AcelRx Pharmaceuticals, Redwood City, California (P.P.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Dahan","sequence":"additional","affiliation":[{"name":"From P Less Than, San Francisco, California (D.M.F.); Certara Strategic Consulting, Princeton, New Jersey (P.C., D.R.W.); Leiden University Medical Center, Leiden, The Netherlands (A.D.); and AcelRx Pharmaceuticals, Redwood City, California (P.P.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela P.","family":"Palmer","sequence":"additional","affiliation":[{"name":"From P Less Than, San Francisco, California (D.M.F.); Certara Strategic Consulting, Princeton, New Jersey (P.C., D.R.W.); Leiden University Medical Center, Leiden, The Netherlands (A.D.); and AcelRx Pharmaceuticals, Redwood City, California (P.P.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20241223","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0033-1351138","article-title":"Postoperative pain control.","volume":"26","year":"2013","journal-title":"Clin Colon Rectal Surg"},{"key":"R2-20241223","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.5811\/westjem.2015.10.28454","article-title":"The changing use of intravenous opioids in an emergency department.","volume":"16","year":"2015","journal-title":"West J Emerg Med"},{"key":"R4-20241223","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jemermed.2011.07.030","article-title":"IV access difficulty: Incidence and delays in an urban emergency department.","volume":"42","year":"2012","journal-title":"J Emerg Med"},{"key":"R5-20241223","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jemermed.2017.04.002","article-title":"Predictors and delays associated with the need for advanced techniques for intravenous access.","volume":"53","year":"2017","journal-title":"J Emerg Med"},{"key":"R6-20241223","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200241090-00003","article-title":"Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications.","volume":"41","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R7-20241223"},{"key":"R8-20241223"},{"key":"R9-20241223"},{"key":"R10-20241223"},{"key":"R11-20241223"},{"key":"R12-20241223","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/AAP.0b013e3182791157","article-title":"Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain.","volume":"38","year":"2013","journal-title":"Reg Anesth Pain Med"},{"issue":"suppl 2","key":"R13-20241223","first-page":"S198","article-title":"A dose-finding study of sufentanil sublingual microtablets for the management of postoperative bunionectomy pain.","volume":"77","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"key":"R14-20241223","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/AAP.0000000000000152","article-title":"Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: A randomized, placebo-controlled study.","volume":"40","year":"2015","journal-title":"Reg Anesth Pain Med"},{"key":"R15-20241223","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/ALN.0000000000000746","article-title":"Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: A randomized, placebo-controlled study.","volume":"123","year":"2015","journal-title":"Anesthesiology"},{"key":"R16-20241223","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/papr.12531","article-title":"Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: A randomized, placebo-controlled, phase-3 study.","volume":"17","year":"2017","journal-title":"Pain Pract"},{"key":"R17-20241223","article-title":"An open-label study of sufentanil sublingual tablet 30 mcg in patients with postoperative pain.","year":"2017","journal-title":"Pain Med"},{"key":"R18-20241223","article-title":"Sufentanil sublingual tablet 30 mcg for moderate-to-severe acute pain in the emergency department.","year":"2017","journal-title":"Am J Emerg Med"},{"key":"R19-20241223","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.clinthera.2014.11.001","article-title":"Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers.","volume":"37","year":"2015","journal-title":"Clin Ther"},{"key":"R20-20241223","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00000542-199101000-00007","article-title":"Electroencephalographic quantitation of opioid effect: Comparative pharmacodynamics of fentanyl and sufentanil.","volume":"74","year":"1991","journal-title":"Anesthesiology"},{"key":"R21-20241223","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1399-6576.1991.tb03277.x","article-title":"Postoperative patient-controlled analgesia with sufentanil: Analgesic efficacy and minimum effective concentrations.","volume":"35","year":"1991","journal-title":"Acta Anaesthesiol Scand"},{"key":"R22-20241223","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/papr.12238","article-title":"Sufentanil sublingual tablet system vs. intravenous patient-controlled analgesia with morphine for postoperative pain control: A randomized, active-comparator trial.","volume":"14","year":"2014","journal-title":"Pain Pract"},{"key":"R23-20241223","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000542-199101000-00010","article-title":"Pharmacokinetics, pharmacodynamics, and rational opioid selection.","volume":"74","year":"1991","journal-title":"Anesthesiology"},{"key":"R24-20241223","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000542-199203000-00003","article-title":"Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.","volume":"76","year":"1992","journal-title":"Anesthesiology"},{"key":"R25-20241223","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0091270006297749","article-title":"Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate.","volume":"47","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R26-20241223","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism.","volume":"84","year":"2009","journal-title":"Mayo Clin Proc"}],"updated-by":[{"DOI":"10.1097\/aln.0000000000002383","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000}}],"container-title":["Anesthesiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/pubs.asahq.org\/anesthesiology\/article-pdf\/128\/5\/943\/382081\/20180500_0-00019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/anesthesiology.pubs.asahq.org\/article.aspx?volume=128&page=943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:17:04Z","timestamp":1784899024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/ALN.0000000000002145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/aln.0000000000002145","relation":{},"ISSN":["0003-3022"],"issn-type":[{"value":"0003-3022","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}